Human PLA2G2A adenoviral particles

The PLA2G2A gene encodes group IIA secretory phospholipase A2 (sPLA2-IIA), a calcium-dependent enzyme that hydrolyzes sn-2 phospholipids to release free fatty acids and lysophospholipids. The protein plays a key role in inflammatory responses, lipid metabolism, and host defense mechanisms. Elevated expression of PLA2G2A has been associated with a variety of pathological conditions, including atherosclerosis, rheumatoid arthritis, and cancer, and it is involved in regulating cell proliferation, apoptosis, and immune regulation. Its enzymatic activity and signaling properties make it a potential target for drug development, especially in the field of inflammation-related diseases.

Human PLA2G2A adenoviral particles are recombinant adenoviral vectors designed to deliver the PLA2G2A gene to target cells for overexpression studies. These particles take advantage of the high transduction efficiency and broad tropism of adenoviruses to enable stable gene expression in both dividing and non-dividing cells. The adenoviral backbone is often modified to ensure safety, such as deletion of the E1/E3 regions, rendering the virus replication-incapable while maintaining high levels of transgene expression. PLA2G2A adenoviral particles are widely used in in vitro and in vivo studies to investigate the role of this gene in inflammation, cancer progression, and lipid-mediated signaling pathways. Applications include functional analysis, mechanistic studies, and preclinical evaluation of the therapeutic potential of PLA2G2A.